Therapeutic Options for Atherogenic Dyslipidemia in Diabetes
Author Information
Author(s): Alexander Tenenbaum, Enrique Z. Fisman, Michael Motro, Yehuda Adler
Primary Institution: Cardiac Rehabilitation Institute, the Chaim Sheba Medical Center
Hypothesis
Patients with insulin-resistant syndromes such as diabetes and/or metabolic syndrome might benefit the most from therapy with fibrates.
Conclusion
Combination therapy may offer desirable benefits in patients with combined hyperlipidemia compared to statin monotherapy.
Supporting Evidence
- Fibrates have been shown to reduce triglyceride levels and increase HDL-cholesterol.
- Gemfibrozil treatment led to a significant reduction in major cardiovascular events.
- Fenofibrate reduced the incidence of total cardiovascular events by 11%.
- Bezafibrate has demonstrated beneficial effects on glucose metabolism and insulin sensitivity.
Takeaway
This study looks at how different medicines can help people with diabetes and high cholesterol. Using a mix of medicines might work better than just one type.
Methodology
The study reviews various lipid-lowering approaches in patients with mixed atherogenic dyslipidemia.
Potential Biases
Potential bias due to differential use of statins and other therapies affecting outcomes.
Limitations
The study does not provide direct head-to-head comparisons of statins and fibrates in clinical endpoint trials.
Participant Demographics
Participants included subjects aged 50 to 75 years with type 2 diabetes.
Statistical Information
P-Value
0.035
Confidence Interval
0.54–0.95
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website